SOX17 is altered in 2.73% of all cancers with colon adenocarcinoma, breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in SOX17 are SOX17 Amplification (1.12%), SOX17 Loss (0.07%), SOX17 A96G (0.03%), SOX17 A292T (0.02%), and SOX17 A108V (0.02%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.